- $68.12m
- $43.65m
- $0.92m
Brief: Rafael Holdings Inc Says Ameet Mallik Will Remain In Company's Board Of Directors
Brief: EMA Grants Orphan Drug Designation To Rafael Pharmaceuticals'Devimistat For Treatment Of Patients With Relapsed Or Refractory Burkitt's Lymphoma
NYSE RESUMED RAFAEL HLDN CL B
NYSE RESUMED RAFAEL HLDN CL B
U.S. STOCKS ON THE MOVE-Ford, Hut 8 Mining, Rafael Holdings, Spotify
U.S. STOCKS ON THE MOVE-Tesla, Rafael Holdings, Bitfarms, UP Fintech
Brief: Rafael Holdings Provides Update On Rafael Pharmaceuticals’ Two Phase 3 Trials Of Cpi-613
Rafael Holdings plummets as cancer drug fails late-stage studies
Brief: Rafael Holdings Reports Q4 And Full Year Fiscal 2021 Financial And Operating Results
Brief: Rafael Holdings Inc Says Menachem Ash Voluntarily Resigned As President
Brief: Rafael Holdings Appoints Patrick Fabbio As Chief Financial Officer
Brief: Rafael Holdings Announces Closing Of $104.2 Mln Private Placement
U.S. STOCKS ON THE MOVE-Lordstown Motors, HEXO, Rafael Holdings, Progenity, GeoVax Labs
Rafael Holdings hits near 4-month low on capital raise
Brief: Rafael Holdings Announces $104.2 Million Private Placement
Brief: Rafael Pharmaceuticals Announces Positive Preplanned Interim Futility Analysis Of Pivotal Phase 3 Trial Of CPI-613
Brief: FDA Grants Rafael Pharmaceuticals Orphan Drug Designation For Devimistat
Brief: Rafael Holdings Announces Strategic Merger With Rafael Pharmaceuticals To Form A Focused Late-Stage Clinical Oncology Company
Brief: Rafael Holdings Reports Q3 Loss Per Share Of 15 Cents